This document proposes a prospective medical system of the future that would help physicians with diagnosis, treatment decisions, and monitoring of therapy. It would integrate existing health technologies like computerized physician order entry, clinical decision support systems, and electronic medical records. The system would make personalized treatment recommendations based on a patient's details and test results, using updated guidelines. It would monitor therapy and modify it automatically based on markers of drug concentration and patient improvement. This prospective system aims to standardize and optimize healthcare globally using weekly/monthly updated guidelines and connections to drug safety monitoring centers.
Biostatistics Roles and Responsibilities in Clinical Research | PubricaPubrica
This Presentation explains the Roles and Responsibilities of Biostatistics in clinical research
Biostatistics helps to find answer for research question in Biology, Medicine and Public health
- How a new drug works
- What causes cancer
- what is the reason for many diseases
- How long could a person survive with a particular disease?
Learn More: http://pubrica.com/services/research-services/biostatistics-and-statistical-programming-services/
Contact:
Web: www.pubrica.com
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United kingdom : +44-1143520021
Study of medication appropriateness during hospital stay and revisits in medi...iosrjce
IOSR Journal of Pharmacy and Biological Sciences(IOSR-JPBS) is a double blind peer reviewed International Journal that provides rapid publication (within a month) of articles in all areas of Pharmacy and Biological Science. The journal welcomes publications of high quality papers on theoretical developments and practical applications in Pharmacy and Biological Science. Original research papers, state-of-the-art reviews, and high quality technical notes are invited for publications.
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Quality Use of Medicines means:
• Selecting management options wisely by:
Considering the place of medicines in treating illness and maintaining health, and
recognising that there may be better ways than medicine to manage many disorders.
• Choosing suitable medicines if a medicine is considered necessary so that the best available option is selected by taking into account:
- the individual
- the clinical condition
- risks and benefits
- dosage and length of treatment
- any co-existing conditions
- other therapies
- monitoring considerations
- costs for the individual, the community and the health system as a whole.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RIS...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive
and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be
useful for selecting treatments because they directly predict the response to a treatment. The latter are used
to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease.
Current intelligent systems can be a solution for transferring advancements in molecular biology into
practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis
of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating
domain knowledge in predictive and prognostic models for personalized treatment. Our personalized
medicine support system provides the needed support in complex decisions and can be incorporated into a
treatment guide for selecting molecular targeted therapies.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RIS...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive
and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be
useful for selecting treatments because they directly predict the response to a treatment. The latter are used
to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease.
Current intelligent systems can be a solution for transferring advancements in molecular biology into
practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis
of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating
domain knowledge in predictive and prognostic models for personalized treatment. Our personalized
medicine support system provides the needed support in complex decisions and can be incorporated into a
treatment guide for selecting molecular targeted therapies.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RI...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be useful for selecting treatments because they directly predict the response to a treatment. The latter are used to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease. Current intelligent systems can be a solution for transferring advancements in molecular biology into practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating domain knowledge in predictive and prognostic models for personalized treatment. Our personalized medicine support system provides the needed support in complex decisions and can be incorporated into a treatment guide for selecting molecular targeted therapies.
Biostatistics Roles and Responsibilities in Clinical Research | PubricaPubrica
This Presentation explains the Roles and Responsibilities of Biostatistics in clinical research
Biostatistics helps to find answer for research question in Biology, Medicine and Public health
- How a new drug works
- What causes cancer
- what is the reason for many diseases
- How long could a person survive with a particular disease?
Learn More: http://pubrica.com/services/research-services/biostatistics-and-statistical-programming-services/
Contact:
Web: www.pubrica.com
Email: sales@pubrica.com
WhatsApp : +91 9884350006
United kingdom : +44-1143520021
Study of medication appropriateness during hospital stay and revisits in medi...iosrjce
IOSR Journal of Pharmacy and Biological Sciences(IOSR-JPBS) is a double blind peer reviewed International Journal that provides rapid publication (within a month) of articles in all areas of Pharmacy and Biological Science. The journal welcomes publications of high quality papers on theoretical developments and practical applications in Pharmacy and Biological Science. Original research papers, state-of-the-art reviews, and high quality technical notes are invited for publications.
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Quality Use of Medicines means:
• Selecting management options wisely by:
Considering the place of medicines in treating illness and maintaining health, and
recognising that there may be better ways than medicine to manage many disorders.
• Choosing suitable medicines if a medicine is considered necessary so that the best available option is selected by taking into account:
- the individual
- the clinical condition
- risks and benefits
- dosage and length of treatment
- any co-existing conditions
- other therapies
- monitoring considerations
- costs for the individual, the community and the health system as a whole.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RIS...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive
and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be
useful for selecting treatments because they directly predict the response to a treatment. The latter are used
to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease.
Current intelligent systems can be a solution for transferring advancements in molecular biology into
practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis
of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating
domain knowledge in predictive and prognostic models for personalized treatment. Our personalized
medicine support system provides the needed support in complex decisions and can be incorporated into a
treatment guide for selecting molecular targeted therapies.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RIS...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive
and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be
useful for selecting treatments because they directly predict the response to a treatment. The latter are used
to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease.
Current intelligent systems can be a solution for transferring advancements in molecular biology into
practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis
of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating
domain knowledge in predictive and prognostic models for personalized treatment. Our personalized
medicine support system provides the needed support in complex decisions and can be incorporated into a
treatment guide for selecting molecular targeted therapies.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RI...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be useful for selecting treatments because they directly predict the response to a treatment. The latter are used to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease. Current intelligent systems can be a solution for transferring advancements in molecular biology into practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating domain knowledge in predictive and prognostic models for personalized treatment. Our personalized medicine support system provides the needed support in complex decisions and can be incorporated into a treatment guide for selecting molecular targeted therapies.
PERSONALIZED MEDICINE SUPPORT SYSTEM: RESOLVING CONFLICT IN ALLOCATION TO RIS...hiij
Treatment management in cancer patients is largely based on the use of a standardized set of predictive
and prognostic factors. The former are used to evaluate specific clinical interventions, and they can be
useful for selecting treatments because they directly predict the response to a treatment. The latter are used
to evaluate a patient’s overall outcomes, and can be used to identify the risks or recurrence of a disease.
Current intelligent systems can be a solution for transferring advancements in molecular biology into
practice, especially for predicting the molecular response to molecular targeted therapy and the prognosis
of risk groups in cancer medicine. This framework primarily focuses on the importance of integrating
domain knowledge in predictive and prognostic models for personalized treatment. Our personalized
medicine support system provides the needed support in complex decisions and can be incorporated into a
treatment guide for selecting molecular targeted therapies.
Patient Reported Outcomes (PRO) - Challenge and potential solutions.
Why and how can medical device and pharmaceutical companies, as well as the entire healthcare sector, leverage patient engagement with next-generation ePRO solutions?
Discover our white paper...
A study on prescription pattern and rational use of statins in tertiary care ...SriramNagarajan16
Objectives
Our objectives are to evaluate prescription pattern and rational use of statins in a tertiary care corporate hospital.
Methodology
It was a prospective observational study conducted for a period of 6 months and included various departments of 300
bedded multi specialty tertiary care corporate hospital. A total of 200 patients were included and the study criteria
was inpatients and induvial more than 18 years of either gender who are prescribed with HMG-CoA reductase
inhibitors.
Results
In the present study 200 patients belonged to the age group of above 18 years, out of which about 65% were male
and 35% were female. Atorvastatin (67%) was prescribed mostly and Rosuvastatin (29.5%) was also used.
Conclusion
It is finally concluded that Rational and prophylactic use of statins can reduce further complications of Diabetes
Mellitus (DM) and cardiac events.
Statins treatment is favourable in long term treatment of diseases, it is most effectively used in treatment of serious
disease conditions which has shown its immense therapeutic role in treatment
Epidemiology is the study of occurrence, distribution and determinants of health and
diseases or disorders in man and its application in controlling health problems.
Epidemiology has by tradition two major areas.
First is the study of infectious diseases that spread to large populations, i.e., epidemics.
The second is the study of chronic diseases.
Epidemiological studies help to solve such health problems and provide a basis for
improving living conditions of the people.
During its progress and development, epidemiology has made available precise and
strict methodologies for the study of diseases.
Pharmacology is the study of the effects of drugs.
Clinical Pharmacology is the study of the effects of drugs in humans, It is traditionally
divided into two basic areas namely:
1. Pharmacokinetics
2. Pharmacodynamics.
Pharmacokinetics is the study of the relationship between dose administered of a drug
and the serum or blood level achieved, it deals with absorption, distribution, metabolism
and excretion.
Epidemiology is the study of the distribution and determinants of diseases in
populations.
Epidemics is the study of chronic/ infectious diseases in large populations.
Pharmacoepidemiology is the study of the use of and the effects of drugs in large
number of people.
It involves the examination of a single individual or large groups of people followed for
many years.
It involves gathering & analysis of information in order to identify possible causation &
related factors, that can be applied in clinical practice to group of people & also to
individuals undergoing treatment.
Applications of statistics in medical Research and HealthrMuhammadNafees42
This will help you to understand the applications of basic statistics.The application of stat in medical health and research.
#nafeesupdates
#nafeesmedicos
Similar to A prospective-medical-system-of-the-futurea-complete-health-care-system (20)
Practice of Indian Physicians Towards Use of Calcium Channel Blockers in the ...Mahdy Ali Ahmad Osman
A journal club on the Practice of Indian Physicians Towards Use of Calcium Channel Blockers in the Management of
Hypertension A Paper Based Questionnaire Survey, research.
TDM is increasingly being used in clinical practice in order to improve the therapeutic outcome and reducing the toxicity in HIV infection.
The use of TDM requires certain criteria in order to interpret the plasma concentrations appropriately.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
2. Citation: Osman MAA (2018) A Prospective Medical System of the Future/a Complete Health Care System. J Gen Pract 6: 371.
Page 2 of 4
Volume 6 • Issue 4 • 1000371
J Gen Pract, an open access journal
ISSN: 2329-9126
The Design
Aprospectivemedicalsystemofthefutureitisbasedonmodernizing
and integrating of some health information technology systems for
example: computerized physician order entry (COPE), Triage, clinical
decision support system (CDSS) types (diagnosis decision support
systems DDSS, case-based reasoning CBR, Knowledge-based and Non-
knowledge-based) and other new health information technologies
[computer therapy monitoring and computer drug dosing control based
on correlation between the drug pharmacokinetic (drug concentration)
and pharmacodynamics (patient improvement markers example fever,
heart rate, poising concentration) besides prevent drug toxicity and
potential doses related side effects], automatic therapy monitoring,
evaluating and remodifying. All linked together.
The Flow Chart
The diagnosis instructions and personalization of therapy will be
analysed from the patient data, which includes Age, Gender, maternal
state, chief compliant, symptoms, vital sings, past medical and
medications history (PMH) and ethnicity (biopsychosocial model).
After entering of the patient data the system/software will determining
the priority of patients (triage) and giving instructions for next step
either diagnosis for simple medicals conditions or diagnostics tests
that should done. The laboratories centres/departments will being
connected with the system/software in order to receive the diagnostics
values/results/findings, afterward the system/software will compare the
findings with the normal (analyse) to give the report of the result and
the final diagnosis what is more complications if it founded (Figures 1
and 2).
Then this followed by the recommendations by the system/
software for the best management option for the patient (whether
it is non-pharmacological or pharmacological/ options). Non-
pharmacological options for example: lifestyle modification, surgery,
cognitive behaviour therapy (CBT). For the pharmacological option the
personalize pharmacotherapy will be by the analysis/compare by the
system/software logic of patient data, diagnosis, laboratories findings
with the guidelines and recommendations that stored in the system.
The optimize therapy it is based on guidelines and recommendations,
age ,ethnicity, comorbidity, contraindications, cost), rights doses
[based on body weight ,age ethnicity (population-pharmacokinetic
like: pharmacogenetic, conditions alter pharmacokinetic, time
depending killing, concentration depending killing], the best route
of administration (based on pharmacokinetic-pharmacodynamics
approach, the ideal administration time (based on chronotherapy),
prevent drugs interactions (drug-drug, drugs-diseases, drugs-food,
drugs-recreational substances interactions), patient personalize
advice and counselling. Then evaluation and monitoring of therapy
(for examples evaluation of response and improvement, monitoring
parameters, computer therapy monitoring and computer drug dosing
control in certain cases for example: some chemotherapy agents, time/
concentrationdependkillingdrugsinhighresistanceorsuperinfections,
renal/hepatic impair patient) and follow-up, by the system whether
during hospitalizing (the system connected with the medical devices)
or in the follow up with simultaneously automatic regenerating of
protocols, guidelines, reconditions, adverse drug reactions reporting
and studies and researches supplying. The system will ensure covering
of the six criteria that measure and describe quality of care in health.
Demonstrate Example (Figure 3 and Table 1)
Advantages
Prevention of medical errors; reduce the work load and time
pressure. Minimize/manipulate the side effects and enhance treatment
outcome (Minimum treatment risks safe care). Efficacy and accuracy
of the decisions. Data retrieving and regeneration (self-develop
system/auto-updating, the data will be easily extracted for adverse
drugs reactions monitoring authorities and for studies and research).
Will possibility for covering all guidelines and recommendations,
combined together or based on selection separately. The system
covers and supports all aspects of clinical tasks triage, diagnosis,
treatment plan/decision, personal therapy, therapy evaluation and
monitoring. Considerations of chronotherapy, pharmacoeconomics,
pharmacokinetics, pharmacodynamics approaches and computer
therapy monitoring and computer drug dosing control.
Limitations
System development will have required time, so it will be better at
firsttodesignthreedifferentsystems:triage,diagnosissystem,Treatment
decision system, monitoring and evaluation system, then combine all as
one system. Cases that are more complex will require more time to be
recognized by the system. Healthcare professionals’ adherence to the
system will be required time. There are many guidelines (American,
British, European etc...), but it can be combined and integrated or
separated in the system as an option and preselection by healthcare
professionals to use combined or used particular guidelines.
Figure 1: The diagnosis instructions and personalization of therapy will be
analysed from the patient data, which includes Age, Gender, maternal state,
chief compliant, symptoms, vital sings, past medical and medications history
(PMH) and ethnicity (biopsychosocial model).
Figure 2: Recommendations by the system/software for the best management
option for the patient (whether it is non-pharmacological or pharmacological/
options).
3. Citation: Osman MAA (2018) A Prospective Medical System of the Future/a Complete Health Care System. J Gen Pract 6: 371.
Page 3 of 4
Volume 6 • Issue 4 • 1000371
J Gen Pract, an open access journal
ISSN: 2329-9126
Figure 3: The system will ensure covering of the six criteria that measure and describe quality of care in health.
The Current Medical Procedure A Prospective Medical System of the Future (PMSF)
Workload and Time Pressure
High workload and time pressure is common
[3,4,19,20].
Saving time it is known one of advantages of CDSS (clinical
decision support system) [7,21] although it cover one or two
clinical tasks. That is mean a PMSF will lead to significant
decrease in workload and time pressure.
Medical Errors
One of the most healthcare challenges
(Causatives vary from misdiagnosis, inaccurate
treatment or from physician, pharmacist, nurse)
[5,6,22,23].
This has proven by reduction in medical errors due to use of
CDSS (clinical decision support system) or computerized provider
order entry (CPOE) systems [8,9,24,25].
Efficacy and Safety
Likely to be poor since it is influence by
medical errors.
PMSF will improve efficacy and safety by selection of appropriate
diagnosis and treatment, prevention of medical errors, evaluation
and monitoring of therapy.
Data Retrieving Regeneration of guidelines and
recommendations.
Data retrieving for non-electronic health record
it is time consuming, uneconomical, lack of
accuracy.
Regeneration in majority it is manually.
Will save time and money, high accuracy this in term of data
retrieving.
Regeneration will be automatically.
Considerations of biopsychosocial model,
chronotherapy, pharmacoeconomics,
pharmacokinetics, pharmacodynamics approaches
and computer therapy monitoring and computer drug
dosing control.
It is rare apply of this approaches in current
medical procedure; due to training healthcare
professionals in this approaches. Besides of
complexity of the approaches.
PMSF will programmed with this approaches without need of
healthcare professionals knowledge about them and computer is
easily can solve complexity.
Adverse drug reaction reporting Procedure
The current ADRs reporting procedure depend
on paper and electronic entering of the data
and this result in discouraging of reporting.
According to a new study lack of time is one of
the barriers of ADRs reporting.
Whereas ADRs reporting procedure is proposed to be
spontaneously/automatically.
Data Collection
In most cases, data collect and then (may
decoded) enter into the computer in order to
analysis.
The Data/specific require data will extract from the system (and
decode automatically if it required) and analysis, without needing
of collection and entering.
Table 1: Differences between current medical procedure and a prospective medical system of the future.
Conclusion
A prospective medical system of the future will be inevitable for
introduction of the modernization of the health care processes; the best
treatment outcome (benefits). Moreover, minimum risks apart from
its practically user friendly (healthcare professionals); saving effort
and money; accelerate the health care process; ADRS reporting, make
4. Citation: Osman MAA (2018) A Prospective Medical System of the Future/a Complete Health Care System. J Gen Pract 6: 371.
Page 4 of 4
Volume 6 • Issue 4 • 1000371
J Gen Pract, an open access journal
ISSN: 2329-9126
studies and research easier and faster what is more in a modern method.
Acknowledgment
I would like to express my special thanks of gratitude to my GOD, my mother
Seham Mahdy Elasha; my father Ali Ahmad Osman; Mrs. Athensia Sevastaki
Belfast Met; JKKN College of Pharmacy Komarapalayam, Tamil Nadu, India; JSS
College of Pharmacy, Ooty, Tamil Nadu, India and finally The Government of the
United Kingdom.
References
1. The impact of computers in our daily lives computer science essay. Ukessays.
com 2016.
2. Artificial Intelligence in Medicine 42. Dl.acm.org. 2018.
3. Alonso CP, Martínez GL, Carrasco J, Solà I, Qureshi S (2011). The updating
of clinical practice guidelines: insights from an international survey. Implement
Sci 6.
4. Fricker L (2016) Drug discovery over the past thirty years: Why aren’t there
more new drugs. Einstein J Biol Medi, 29: 61.
5. https://epilepsychicago.org/epilepsy/treatment/factors-influencing-drug-
selection/
6. Proulx J (2014) Risk factors of adverse drug reaction–related hospitalizations
among seniors, 2006 To 2011. Value in Health 17: 16.
7. Misdiagnosis (1953) The Lancet 261: 1034.
8. Michon K, Attorney (2018) Medical malpractice: Misdiagnosis and delayed
diagnosis.
9. Slight SP, Howard R, Ghaleb M, Barber N, Franklin BD, et al. (2013) The
causes of prescribing errors in English general practices: A qualitative study. Br
J Gen Pract 63: e713-720.
10. Dean B, Schachter M, Vincent C, Barber N (2002) Causes of prescribing errors
in hospital inpatients: A prospective study. The Lancet 359: 1373-1378.
11. Bates DW, Boyle DL, Vander Vliet MB, Schneider J, Leape L (1995) Relationship
between medication errors and adverse drug events. J Gen Intern Med 10:
199-205.
12. Gill P, Stewart K, Treasure E, Chadwick B (2008) Methods of data collection in
qualitative research: Interviews and focus groups. BDJ 204: 291.
13. Schobel J, Pryss R, Schickler M, Reichert M (2016) June. Towards flexible
mobile data collection in healthcare. In Computer-Based Medical Systems
(CBMS) 2016.
14. Engel GL (1977) The need for a new medical model: A challenge for
biomedicine. Science 196: 129-136.
15. Engel GL (1980) The clinical application of the biopsychosocial model. Am J
Psychiatry 137: 535-544.
16. Frankel RM, Quill TE, McDaniel SH (2003) The Biopsychosocial Approach:
Past, Present,Future.University of Rochester Press, Rochester, NY.
17. Ransom ER (2008). The healthcare quality book: vision, strategy, and tools.
Chicago: Health Administration Press.
18. Chassin MR, Galvin RW (1998). The urgent need to improve health care quality:
Institute of Medicine National Roundtable on Health Care Quality. Jama, 280:
1000-1005.
19. McVicar A (2003) Workplace stress in nursing: A literature review. J Adv Nurs
44: 633-642.
20. MarineA, Ruotsalainen JH, Serra C, Verbeek JH (2006) Preventing occupational
stress in healthcare workers. Cochrane Database of Syst Rev 4 : CD002892.
21. Rodziewicz TL, Hipskind JE (2018) Medical error prevention. In StatPearls
[Internet]. StatPearls Publishing.
22. Cheragi MA, Manoocheri H, Mohammadnejad E, Ehsani SR (2013) Types and
causes of medication errors from nurse’s viewpoint. Iran J Nurs Midwifery Res
18: 228.
23. Murphy EV (2014) Clinical decision support: Effectiveness in improving quality
processes and clinical outcomes and factors that may influence success. Yale
J Biol Med 87: 187.
24. Jia P, Zhang L, Chen J, Zhao P, Zhang M (2016) The effects of clinical decision
support systems on medication safety: An overview. PloS one 11: p.e0167683.
25. Radley DC, Wasserman MR, Olsho LE, Shoemaker SJ, Spranca MD, et
al. (2013) Reduction in medication errors in hospitals due to adoption of
computerized provider order entry systems. J Am Med Inform Assoc 20: 470-
476.